Eli Lilly launched the Lilly Change the Course Commitment, aiming to treat as many people with diabetes and obesity in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries before 2040. Lilly says that for every four people in high-income countries who can access its diabetes and obesity medicines, only one person in LMICs can reach them. The initiative will focus on adapting medicine development, registering innovative treatments in more LMICs and strengthening primary health systems through partnerships with regulators, health authorities, global health organizations and NGOs. Lilly said its completed 30x30 initiative expanded access to quality healthcare for 40 million people in resource-limited settings in 2025, surpassing its goal of reaching 30 million people annually by 2030 five years ahead of schedule. The company plans to track treatment reach in its annual Sustainability Report and at major global health forums.